Benoit Blanchet
Overview
Explore the profile of Benoit Blanchet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
1332
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Inouri T, Noel J, Blanchet B, Thomas-Schoemann A
Support Care Cancer
. 2024 Sep;
32(10):648.
PMID: 39254772
Concomitant direct oral anticoagulants (DOACs) and tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor (anti-VEGF TKI) have been associated with a higher risk of bleeding. Nevertheless, concomitant administration seems...
2.
Alexandre J, Oudard S, Golmard L, Campedel L, Mseddi M, Ladoire S, et al.
Clin Pharmacokinet
. 2024 Jul;
63(7):1025-1036.
PMID: 38963459
Background And Objective: Trough abiraterone concentration (ABI C) of 8.4 ng/mL has been identified as an appropriate efficacy threshold in patients treated for metastatic castration-resistant prostate cancer (mCRPC). The aim...
3.
Alle G, Guettrot-Imbert G, Larosa M, Murarasu A, Lazaro E, Morel N, et al.
Rheumatology (Oxford)
. 2024 Jun;
64(3):1225-1233.
PMID: 38837707
Objectives: Data about hydroxychloroquine (HCQ) levels during pregnancy are sparse. We assessed HCQ whole-blood levels at first trimester of pregnancy as a potential predictor of maternal and obstetric/fetal outcomes in...
4.
Sterle M, Puszkiel A, Burlot C, Pereira E, Bellesoeur A, De Percin S, et al.
Ther Adv Med Oncol
. 2024 Apr;
16:17588359241248328.
PMID: 38665845
Background: Olaparib is an inhibitor of the human poly-(ADP-ribose)-polymerase enzymes (PARP1/2) needed to repair single-strand DNA breaks. It is used in breast, ovarian, prostate and pancreatic cancer. Objectives: This work...
5.
Puszkiel A, Bianconi G, Pasquiers B, Balakirouchenane D, Arrondeau J, Boudou-Rouquette P, et al.
Br J Cancer
. 2024 Mar;
130(11):1866-1874.
PMID: 38532102
Background: Reducing nivolumab dose intensity could increase patients' life quality and decrease the financial burden while maintaining efficacy. The aims of this study were to develop a population PK model...
6.
Blanchet B, Xu-Vuilard A, Jouinot A, Puisset F, Combarel D, Huillard O, et al.
Br J Cancer
. 2024 Jan;
130(6):961-969.
PMID: 38272963
Background: Interindividual pharmacokinetic variability may influence the clinical benefit or toxicity of cabozantinib in metastatic renal cell carcinoma (mRCC). We aimed to investigate the exposure-toxicity and exposure-response relationship of cabozantinib...
7.
Deru V, Tiezzi F, Carillier-Jacquin C, Blanchet B, Cauquil L, Zemb O, et al.
Genet Sel Evol
. 2024 Jan;
56(1):8.
PMID: 38243193
Background: Improving pigs' ability to digest diets with an increased dietary fiber content is a lever to improve feed efficiency and limit feed costs in pig production. The aim of...
8.
Balakirouchenane D, Seban R, Groussin L, Puszkiel A, Cottereau A, Clerc J, et al.
Thyroid
. 2023 Sep;
33(11):1327-1338.
PMID: 37725566
BRAF and MEK inhibitors are cornerstones of the redifferentiation strategy in metastatic radioactive iodine (RAI)-resistant mutant thyroid cancers. We explored the exposure-toxicity relationship for dose-limiting toxicity (DLT) onset in patients...
9.
Tardy C, Puszkiel A, Boudou-Rouquette P, De Percin S, Alexandre J, Berge M, et al.
Cancer Chemother Pharmacol
. 2023 Aug;
93(2):169-175.
PMID: 37620675
Purpose: Pazopanib is approved in advanced renal cell carcinoma (RCC) and soft-tissue sarcoma at a flat-fixed dose despite a large pharmacokinetics interindividual variability and a narrow therapeutic index. To our...
10.
Nguyen Y, Blanchet B, Urowitz M, Hanly J, Gordon C, Bae S, et al.
Arthritis Rheumatol
. 2023 Jul;
75(12):2195-2206.
PMID: 37459273
Objective: The goals of this study were to assess the associations of severe nonadherence to hydroxychloroquine (HCQ), objectively assessed by HCQ serum levels, and risks of systemic lupus erythematosus (SLE)...